312 related articles for article (PubMed ID: 28150200)
1. Engineering Well-Characterized PEG-Coated Nanoparticles for Elucidating Biological Barriers to Drug Delivery.
Yang Q; Lai SK
Methods Mol Biol; 2017; 1530():125-137. PubMed ID: 28150200
[TBL] [Abstract][Full Text] [Related]
2. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation.
Yang Q; Jones SW; Parker CL; Zamboni WC; Bear JE; Lai SK
Mol Pharm; 2014 Apr; 11(4):1250-8. PubMed ID: 24521246
[TBL] [Abstract][Full Text] [Related]
3. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
4. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.
Suk JS; Xu Q; Kim N; Hanes J; Ensign LM
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):28-51. PubMed ID: 26456916
[TBL] [Abstract][Full Text] [Related]
5. Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo.
Du XJ; Wang JL; Liu WW; Yang JX; Sun CY; Sun R; Li HJ; Shen S; Luo YL; Ye XD; Zhu YH; Yang XZ; Wang J
Biomaterials; 2015 Nov; 69():1-11. PubMed ID: 26275857
[TBL] [Abstract][Full Text] [Related]
6. Identification of polyethylene glycol-resistant macrophages on stealth imaging in vitro using fluorescent organosilica nanoparticles.
Nakamura M; Hayashi K; Nakano M; Kanadani T; Miyamoto K; Kori T; Horikawa K
ACS Nano; 2015 Feb; 9(2):1058-71. PubMed ID: 25629765
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles with dense poly(ethylene glycol) coatings with near neutral charge are maximally transported across lymphatics and to the lymph nodes.
McCright J; Skeen C; Yarmovsky J; Maisel K
Acta Biomater; 2022 Jun; 145():146-158. PubMed ID: 35381399
[TBL] [Abstract][Full Text] [Related]
8. The effect of poly(ethylene glycol) coating and monomer type on poly(alkyl cyanoacrylate) nanoparticle interactions with lipid monolayers and cells.
Baghirov H; Melikishvili S; Mørch Y; Sulheim E; Åslund AKO; Hianik T; de Lange Davies C
Colloids Surf B Biointerfaces; 2017 Feb; 150():373-383. PubMed ID: 27842930
[TBL] [Abstract][Full Text] [Related]
9. Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.
Xu Q; Ensign LM; Boylan NJ; Schön A; Gong X; Yang JC; Lamb NW; Cai S; Yu T; Freire E; Hanes J
ACS Nano; 2015 Sep; 9(9):9217-27. PubMed ID: 26301576
[TBL] [Abstract][Full Text] [Related]
10. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
11. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
12. Assessment of PEG on polymeric particles surface, a key step in drug carrier translation.
Rabanel JM; Hildgen P; Banquy X
J Control Release; 2014 Jul; 185():71-87. PubMed ID: 24768790
[TBL] [Abstract][Full Text] [Related]
13. The effect of surface poly(ethylene glycol) length on in vivo drug delivery behaviors of polymeric nanoparticles.
Wang JL; Du XJ; Yang JX; Shen S; Li HJ; Luo YL; Iqbal S; Xu CF; Ye XD; Cao J; Wang J
Biomaterials; 2018 Nov; 182():104-113. PubMed ID: 30114562
[TBL] [Abstract][Full Text] [Related]
14. Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.
Huang M; Wu W; Qian J; Wan DJ; Wei XL; Zhu JH
Acta Pharmacol Sin; 2005 Dec; 26(12):1512-8. PubMed ID: 16297352
[TBL] [Abstract][Full Text] [Related]
15. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
16. PEGylated nanocarriers for systemic delivery.
Jain NK; Nahar M
Methods Mol Biol; 2010; 624():221-34. PubMed ID: 20217599
[TBL] [Abstract][Full Text] [Related]
17. Critical parameters in the pegylation of gold nanoshells for biomedical applications: an in vitro macrophage study.
Kah JC; Wong KY; Neoh KG; Song JH; Fu JW; Mhaisalkar S; Olivo M; Sheppard CJ
J Drug Target; 2009 Apr; 17(3):181-93. PubMed ID: 19016072
[TBL] [Abstract][Full Text] [Related]
18. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles.
Sant S; Poulin S; Hildgen P
J Biomed Mater Res A; 2008 Dec; 87(4):885-95. PubMed ID: 18228249
[TBL] [Abstract][Full Text] [Related]
19. [The use of shells made of poly(ethylene glycol) and chitosan to ensure the biocompatibility of nanoparticles in biomedical applications].
Kubiak T
Polim Med; 2014; 44(2):119-27. PubMed ID: 24967783
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice.
Shalgunov V; Zaytseva-Zotova D; Zintchenko A; Levada T; Shilov Y; Andreyev D; Dzhumashev D; Metelkin E; Urusova A; Demin O; McDonnell K; Troiano G; Zale S; Safarovа E
J Control Release; 2017 Sep; 261():31-42. PubMed ID: 28611009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
